GLP-1 Daily: Ozempic & Wegovy News — Lantern Podcasts
GLP-1 Daily
Follow GLP-1 Daily across the charts and keep up with new listener reviews. Get the updates in your inbox.
Track this podcast · 7 days freeCard required. Cancel anytime. Choose your plan at signup.
You're on a GLP-1 — or you're about to start one — and you don't have time to sift Facebook groups, press releases, and breathless headlines to figure out what actually changed today. GLP-1 Daily does that in eight minutes every weekday morning. Anchor Cassidy separates real label changes from pharma spin, while cohost Silvara tracks the cost and access story: prior authorization walls, employer-plan shifts, compounding-pharmacy enforcement, and who keeps getting left out of the semaglutide and tirzepatide conversation. We cover FDA decisions, clinical trial readouts, supply and shortage updates, and safety or side-effect news — everything framed around one question: does this change what you should ask your clinician today? Every efficacy figure is cited; company-reported data is flagged as such. We skip celebrity weight-loss content, before-and-after photos, and uncited miracle claims. If you take Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or any oral GLP-1 agonist, this is your morning briefing. Real GLP-1 drug news, real patient focus, no fluff.
Sign up to track rankings and reviews from Spotify, Apple Podcasts and more.